To reach these high ambitions, we foster a culture of transparency, based on open exchange across the entire organization. We are solution-oriented in our thinking, and we do more with less while genuinely enjoying our daily experiences.
We provide our employees with exciting opportunities for professional growth. We work collaboratively to progress our drug portfolio and build a commercial infrastructure.
Our behaviors describe the mindset expected of Idorsia employees to create an entrepreneurial and innovation-driven culture
Date of birth: October 9, 1971
Nationality: Dutch
Education: University of Amsterdam.
Professional background: PricewaterhouseCoopers , Actelion (2014-2017), Head of Global Finance & Procurement, Idorsia (2017-2024).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Ltd.
Date of birth: December 27, 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology; Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd; Co-founder and Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion (1997–2009); Chief Scientific Officer, Actelion (2009–2017).
Awards: Officer of the Legion of Honour in France; Doctor honoris causa from the Swiss Federal Institute of Technology Lausanne (EPFL); Prix Suisse 2022 awarded by Initiative Switzerland; Doctor honoris causa from the University of Basel.
Other Group functions: None
Other functions: Vice Chair of Board of Trustees, Marcel Benoist Foundation.
Date of birth: 1979
Nationality: Swiss
Education: Master of law (LL.M.), University of Cambridge, Trinity Hall, United Kingdom; Lic. iur., University of Fribourg, Switzerland; 2006 Bar admission, Canton of Bern.
Professional background: 2007-2012 Associate in Corporate/M&A team at Homburger AG; 2012-2016 Director Legal (heading Corporate Law), Member of Legal & IP Leadership Team, Group Risk Officer at Lonza AG; 2016-2022 General Counsel, Secretary of the Board and Compliance Officer at Molecular Partners AG. 2022-2024, SVP, Group General Counsel at Idorsia and promoted to EVP, Group General Counsel in 2024.
Other Group functions: Member of Idorsia Pharmaceuticals Ltd Board.
Date of birth: May 6, 1976
Nationality: American
Education: Doctor of Medicine (MD) from Harvard Medical School; Master in Public Policy (MPP) focusing on international development at Harvard Kennedy School of Government; Master’s degrees from the Department of Pathology at the University of Cambridge and the Department of Molecular and Cellular Biology at the Harvard Graduate School of Arts and Sciences; Bachelor’s degree from Harvard College.
Professional background: CEO of Idorsia since July 2025. Served as a member on the Idorsia Board of Directors since 2021 and chair of the Nominating, Governance & Compensation Committee (NGCC). Prior to Idorsia, she held various positions at McKinsey & Company: Global Director, Alumni Strategy and Engagement, 2020–2021; Director of Global Development Programs, 2016–2020; Regional Manager, Diversity & Inclusion, 2014–2016; Senior Expert for the McKinsey Global Health Practice, 2003–2014.
Other Group functions: Executive member of the Board of Idorsia Pharmaceuticals Ltd
Other functions: Board Member on four not-for-profit organizations: International Vaccines Institute, American Swiss Foundation, Partners in Health, and TB Alliance.
Date of birth: March 28, 1960
Nationality: Italian
Education: MD, Pisa University, Italy; Postgraduate course in Clinical Pharmacology, Milan University, Italy
Professional background: Various clinical and therapeutic area leadership positions at Rhône-Poulenc Rorer, Novartis, Serono, Merck Serono; Head of Clinical Science, Actelion (2011–2017); Head of Clinical Development, Actelion/Janssen (2017–2019); Head of Therapeutic Areas Unit, Idorsia (2019–2022).
Other Group functions: None
.webp)
Year of birth: 1975
Nationality: Swiss & British
Education: BSc (Hons) degree in Biochemistry from Cardiff University.
Professional background: Began career at Actelion in 2000 as a Research Associate in Drug Discovery Biology, going on to become a Lab Head from 2003 - 2007. Moved into the Investor Relations & Corporate Communications function in a Scientific Communications role in 2007 and held various roles of increasing responsibility until being appointed Head of Corporate Communications from Actelion 2015-2017. Joined Idorsia as Head of Corporate Communications when the company was established in June 2017, assuming the role of Head of Corporate Communications & Investor Relations in March 2025.
Year of birth: 1973
Nationality: French
Education: Pharmacist degree from Pharmacie Paris V in 1998. Specialized master's degree from ESCP Europe Business School in 1999.
Professional background: 2001-2004, worked as a Product Manager Wyeth France. 2004-2012. Joined Roche France where he held several marketing and sales roles of increasing responsibility until he became the Hematology Franchise Leader. 2012-2018, advanced through commercial roles, first regionally and then at global leadership of commercial strategies at Celgene. 2018-2021, led the Access, Pricing and Contracting strategies for Bristol Myers Squibb hematology portfolio. Joined Idorsia as the Commercial Head EUCAN in 2021. Appointed in 2024 as President of the EUCAN region.
Year of birth: 1961
Nationality: Swiss
Education: Master’s degree in English and Romance Philology from the University of Basel; further education and training in Human Resources, Kaderschule Basel, and in Coaching (both individual and team), Luzern.
Professional background: HR Manager and Assistant to the CEO for EFFIX Logiciels, Paris 1990-1991; HR Administration at F.Hoffmann-La Roche AG, Basel 1991-1994; established the HR function as Head of HR at Actelion 1998-2005; various HR roles including Senior Director, Global Human Resources and Member of Global HR Leadership Team for Actelion 2005-2017; joined Idorsia as Senior Director, Global Human Resources and Member of Global HR Leadership Team when the company was established in June 2017 until being appointed to Head of HR in 2024.
Other Group functions: None.
Year of birth: 1968
Nationality: American
Education: BS in Sports Medicine from Marietta College, and holds a MS Ed. in Exercise Science and Wellness from Old Dominion University
Professional background: Prior to his role at Idorsia US, Michael was Vice President, US Hematology Franchise Lead at Takeda Pharmaceuticals. He led the US launch of Xarelto at Johnson & Johnson and has held US and global sales and marketing leadership positions at Tethys Bioscience, Merck and Schering Plough. Served as VP, Head Marketing US at Idorsia US from 2020-2025. Appointed as President/General Manager of Idorsia US in February 2025.
Other Group functions: None.
Year of birth: 1966
Nationality: French
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd. Joined Idorsia as Head of Pharmaceutical Development when the company was established in June 2017.
The Board of the company currently consists of four non-executive members, three of whom are considered by the Board to be independent in character and judgment, and is one executive member. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance valuable experience of Idorsia’s business with fresh perspectives.
Chairman of the Board (since 13 June, 2024)
Date of birth: April 3, 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche Ltd, 1985–1997. Founder of Actelion in 1997 and CEO 2000–2017.
Awards: Doctor honoris causa from the University of Basel.
Other activities and functions: None.
Vice-Chairman and Lead Independent Director (since June 13, 2024); Chairman (from May 13, 2020, to June 13, 2024)
Date of birth: May 6, 1956
Nationality: French
Education: Certified in internal medicine at the Faculty of Medicine, Paris Diderot University (Paris 7).
Professional background: Former Chairman of the Board of Cellartis AB, 2012–2014; Executive Vice President, Chief Operating Officer of Cellectis Group, 2013–2018; CEO of Cellectis Therapeutics, 2012–2013, and CEO of Ectycell, 2012–2014; Managing Director, Head of Global Pharma operations at Pierre Fabre SA, 2010–2011. Various management and EU regional management roles as well as senior corporate functions at Wyeth Pharmaceuticals.
Other activities and functions: Member of the Board of Directors of one non-listed company, Aileens Pharma (Chairman). Senior Advisor at Messier & Associés.
Non-Executive Member (since May 13, 2020)
Date of birth: January 24, 1965
Nationality: American
Education: Master of Laws degrees from Cornell University & New York University and member of the New York State Bar.
Professional background: President, COO, and CFO of National Resilience, Inc., 2020–2024; Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, 2012–2020; Senior Vice President at Celgene, 2006–2012; Held senior roles in business development & tax at Pfizer and began his career at Ernst & Young.
Other activities and functions: Board member of Crispr Therapeutics.
Executive Member (since July 1, 2025)
Date of birth: May 6, 1976
Nationality: American
Education: Doctor of Medicine (MD) from Harvard Medical School; Master in Public Policy (MPP) focusing on international development at Harvard Kennedy School of Government; Master’s degrees from the Department of Pathology at the University of Cambridge and the Department of Molecular and Cellular Biology at the Harvard Graduate School of Arts and Sciences; Bachelor’s degree from Harvard College.
Professional background: CEO of Idorsia since July 2025. Serves as a member on the Idorsia Board of Directors since 2021 and chair of the Nominating, Governance & Compensation Committee (NGCC), 2021-2025. Prior to Idorsia, she held various positions at McKinsey & Company: Global Director, Alumni Strategy and Engagement, 2020–2021; Director of Global Development Programs, 2016–2020; Regional Manager, Diversity & Inclusion, 2014–2016; Senior Expert for the McKinsey Global Health Practice, 2003–2014.
Other Group functions: Executive member of the Board of Idorsia Pharmaceuticals Ltd
Other activities and functions: Board Member on four not for profit organizations: International Vaccines Institute, American Swiss Foundation, Partners in Health, and TB Alliance.
Non-Executive Member (since June 13, 2024)
Date of birth: July 05, 1970
Nationality: Dutch
Education: MBA degree from INSEAD, France and a bachelor’s degree in business from Nyenrode University, the Netherlands.
Professional background: Held various executive positions at Galapagos (Chief Financial Officer and Chief Operating Officer) from 2014-2023, culminating as President from 2021 to June 2023; various executive positions at Sanofi (2001-2014): strategy consultant at Arthur D. Little.
Other activities and functions: Member of the Board and Chairman of the Audit Committee of ProQR Therapeutics since 2019.
Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.
| Executive Member |
Date of AGM of first election |
Date of AGM of end of term |
|
| Jean-Paul Clozel | No | 2017 | 2026 |
| Mathieu Simon | No | 2019 | 2026 |
| Bart Filius | No | 2024 | 2026 |
| Srishti Gupta | Yes | 2021 | 2026 |
| Sandy Mahatme | No | 2020 | 2026 |
| Sandy Mahatme | Chairman |
| Mathieu Simon | Member |
| Bart Filius | Member |
| Bart Filius | Chairman |
| Mathieu Simon | Member |
